IP Library Granted Patent US 12,291,739
Granted Patent B2
US 12,291,739 · App. 17/390,550 · Granted May 6, 2025

Compositions and methods for enriching populations of nucleic acids

Inventors: Timothy A. Blauwkamp (Palo Alto, CA); Fred Christians (Los Altos Hills, CA); Igor D. Vilfan (East Palo Alto, CA); Scott Smith (San Francisco, CA); Michael Kertesz (Menlo Park, CA)
Assignee: Karius, Inc.
C12Q1/6806C12Q1/6888C12Q1/6804C12Q1/6809
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,291,739
App. No.
17/390,550
Granted
May 6, 2025
Kind
B2
Abstract

This disclosure provides methods and compositions that are useful for enriching a particular population of nucleic acids (a “population of interest”) within a complex mixture of nucleic acids. The population of interest may make up a minor portion of a complex mixture of nucleic acids. The methods and compositions provided herein are useful for detecting, predicting, diagnosing, or monitoring a disease or disorder, particularly a disease or disorder caused by a foreign microbe or pathogen.

Claims (36)

1. A method of enriching microbial cell-free nucleic acids in a plasma sample obtained from a mammalian host, the method comprising:

(a) providing the plasma sample from the mammalian host, wherein the plasma sample comprises cell-free nucleic acids comprising mammalian host cell-free nucleic acids and the microbial cell-free nucleic acids; and

(b) removing or physically isolating cell-free nucleic acids of one or more length ranges from the plasma sample, thereby enriching the plasma sample for microbial cell-free nucleic acids in the length interval ranges of:

(i) from about 10 to about 60 base pairs,

(ii) from about 240 to about 280 base pairs,

(iii) from about 425 to about 475 base pairs, or

(iv) any combination thereof.

2. The method of claim 1 , wherein the cell-free nucleic acids comprise cell-free DNA; and wherein (b) comprises removing or physically isolating cell-free DNA of one or more length ranges from the plasma sample, thereby enriching the plasma sample for microbial cell-free DNA in the length interval ranges of (i) from about 10 to about 60 base pairs; (ii) from about 240 to about 280 base pairs; or (iii) from about 425 to about 475 base pairs, or (iv) any combination thereof.

3. The method of claim 1 , wherein (b) comprises removing or physically isolating cell-free nucleic acids of length intervals of about 180 base pairs or multiples thereof or of about 360 base pairs or multiples thereof.

4. The method of claim 1 , wherein (b) comprises removing or physically isolating cell-free nucleic acids of length intervals selected from the group consisting of 150 base pairs or multiples thereof, 160 base pairs or multiples thereof, 170 base pairs or multiples thereof, 190 base pairs or multiples thereof, and any combination thereof.

5. The method of claim 1 , wherein the plasma sample comprises at least five microbial cell-free nucleic acid sequences and the method further comprises detecting the at least five microbial cell-free nucleic acid sequences.

6. The method of claim 1 , wherein the mammalian host is a human host.

7. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from one or more bacterial, viral, fungal, or parasitic genomes.

8. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from bacteria.

9. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from viruses.

10. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from at least one bacterium selected from the group consisting of Bacillus, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Staphylococcus aureus, Streptococcus, Treponema, Vibrio , and Yersinia.

11. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from at least one fungus selected from the group consisting of Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocystis , and Stachybotrys.

12. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from at least one drug-resistant microbial strain selected from the group consisting of Clostridium difficile , carbapenem-resistant Enterobacteriaceae (CRE), drug-resistant Neisseria gonorrhoeae (cephalosporin resistant), multidrug-resistant Acinetobacter , drug-resistant Campylobacter , fluconazole-resistant Candida , extended spectrum B-lactamase producing Enterobacteriaceae (ESBLs), Vancomycin-resistant Enterococcus (VRE), multidrug-resistant Pseudomonas aeruginosa , drug-resistant non-typhoidal Salmonella , drug-resistant Salmonella Typhi , drug-resistant Shigella , methicillin-resistant Staphylococcus aureus (MRSA), drug-resistant Streptococcus pneumonia , drug-resistant tuberculosis (multidrug-resistant (MDR) and extensively drug-resistant (XDR)), multi-drug resistant Staphylococcus aureus , Vancomycin resistant Staphylococcus aureus (VRSA), erythromycin-resistant Streptococcus Group A, and clindamycin-resistant Streptococcus Group B.

13. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from at least one virus selected from the group consisting of Adenovirus, Amur virus, Andes virus, Animal virus, Astrovirus, Avian nephritis virus, Avian Orthoreovirus, Avian Reovirus, Banna virus, Bas-Congo virus, Bat-borne virus, BK virus, Blueberry shock virus, Chicken anaemia virus, Bovine adenovirus, Bovine coronavirus, Bovine herpesvirus 4, Bovine parvovirus, Bulbul coronavirus HKU11, Carrizal virus, Catacamas virus, Chandipura virus, Channel catfish virus, Choclo virus, Coltivirus, Cricket paralysis virus, Crimean-Congo hemorrhagic fever virus, Dobrava-Belgrade virus, El Moro Canyon virus, Elephant endotheliotropic herpesvirus, Epstein-Barr virus, Feline leukemia virus, Foot-and-mouth disease virus, Gou virus, Guanarito virus, Hantavirus, human coronavirus EMC/2012 (HCoV-EMC/2012), Hendra virus, Henipa virus, Hepatitis D, Hepatitis E virus, Human bocavirus, Human herpesvirus type 8, Human metapneumovirus, Imjin virus, Isla Vista virus, JC virus, Junin virus, Khabarovsk virus, Koi herpes virus, Kuniin virus, Lassa virus, Limestone Canyon virus, Lloviu cuevavirus, Lloviu virus, Lujo virus, Machupo virus, Magboi virus, Marburg virus, Melaka virus, Menangle virus, Middle East respiratory syndrome coronavirus, Miniopterus Bat coronavirus 1, Miniopterus Bat coronavirus HKU8, Monkeypox virus, Monongahela virus, Muju virus, Nipah virus, Norovirus group 1, Norovirus group II, Orbivirus, Phytoreovirus, Pipistrellus bat coronavirus HKU5, Porcine adenovirus, Prospect Hill virus, Qalyub virus, Ravn virus, Reston virus, Reticuloendotheliosis virus, Rhinolophus Bat coronavirus HKU2, Roseolovirus, Ross River virus, Rotavirus, Rousettus bat coronavirus HKU9, Saaremaa virus, Sabia virus, Sangassou virus, Sapovirus, Scotophilus Bat coronavirus 512, Serang virus, Severe acute respiratory syndrome virus, Shope papilloma virus, Simian foamy virus, Sin Nombre virus, Smallpox virus, Soochong virus, Sudan ebolavirus, Sudan virus, Tai Forest ebolavirus, Tai Forest virus, Tanganya virus, Thottapalayam virus, Topografov virus, Tremovirus, Tula virus, Turkey coronavirus, Turkeypox virus, Tvlonycteris bat coronavirus HKU4, West Nile virus, Woodchuck hepatitis virus, Zika virus, and Zaire ebolavirus.

14. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from a pathogen selected from the group consisting of a virus, a bacterium, a fungus, a parasite, and a protozoa.

15. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from at least one pathogen selected from the group consisting of Acanthamoeba, Acari, Acinetobacter baumannii, Actinomyces israelii, Actinomyces gerencseriae, Propionibacterium propionicus, Actinomycetona, Eumycetona , Adenoviridae, Alphavirus, Anaplasma genus, Anaplasma phagocytophilum, Ancylostoma braziliense, Ancylostoma duodenale, Necator americanus, Angiostrongylus costaricensis, Anisakis , Arachnida Ixodidae, Argasidae, Arcanobacterium haemolyticum, Archiacanthocephala, Moniliformis moniliformis , Arenaviridae, Ascaris lumbricoides, Aspergillus genus, Babesia B. divergens, B. bigemina, B. equi, B. microfti, B. duncani, Babesia genus, Bacillus cereus, Bacteroides genus, Balamuthia mandrillaris, Balantidium coli, Bartonella hemselae, Baylisascaris genus, Baylisascaris procyonis, Bertiella mucronata, Bertiella studeri , BK virus, Blastocystis, Blastocystis hominis, Bordetella pertussis, Brugia malayi, Brugia timori , Bunyaviridae, Burkholderia cepacia, Burkholderia species, Caliciviridae, Cestoda, Taenia multiceps, Chlamydophila pneumoniae, Chlamydophila psittaci , Cimicidae Cimex lectularius, Clonorchis sinensis, Clonorchis viverrini, Clostridium difficile, Clostridium perfiringens, Coccidioides posadasii, Cochliomyia hominivorax , Colorado tick fever virus (CTFV), Coronaviridae, Corynebacterium diphtheriae, Coxiella burnetii , Crimean-Congo hemorrhagic fever virus, Cryptosporidium, Cyclospora cayetanensis, Demodex folliculorum/brevis/canis , Flaviviruses, Dermatobia hominis, Dicrocoelium dendriticum, Dientamoeba fragilis, Dioctophyme renale, Diphyllobothrium, Diphyllobothrium latum, Dracunculus medinensis, Echinococcus genus, Echinococcus granulosus, Echinococcus multilocularis, E. vogeli, E. Oligarthrus, Ehrlichia chafeensis, Ehrlichia ewingii, Ehrlichia genus, Entamoeba histolytica, Enterobius vermicularis, Enterobius gregorii , Coxsackie A virus, Enterovirus 71 (EV71), Epidermophyton floccosum, Trichophyton rubrum, Trichophyton mentagrophytes , Epstein-Barr Virus (EBV), Escherichia coli 0157: H7, 0111 and 0104: H4, Fasciola gigantica, Fasciolopsis buski , Filarioidea superfamily, Filoviridae, Flaviviridae, Fonsecaea pedrosoi, Francisella tularensis, Fusobacterium genus, Geotrichum candidum, Gnathostoma spinigerum, Gnathostoma hispidum , Group A Streptococcus , Guanarito virus, Haemophilus ducreyi, Haemophilus influenzae, Halicephalobus gingivalis , Heartland virus, Hepadmaviridae, Hepatitis D Virus, Hepatitis E Virus, Hepeviridae, Hortaea werneckii , Human bocavirus (HBOV), Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Human metapneumovirus (hMPV), Hymenolepis nana, Hymenolepis diminuta, Isospora belli , JC virus, Junin virus, Kingella kingae, Klebsiella granulomatis, Lassa virus, Linguatula serrata, Loa loafilaria, Lymphocytic choriomeningitis virus (LCMV), Machupo virus, Malassezia genus, Mansonella streptocerca, Marburg virus, Metagonimus yokagawai , Microsporidia phylum, Middle East respiratory syndrome coronavirus, Molluscum contagiosum virus (MCV), Monkeypox virus, Mucorales order (Mucormycosis), Entomophthorales order (Entomophthoramycosis), Mumps virus, Mycobacterium lepromatosis, Mycobacterium ulcerans, Mycoplasma pneumoniae, Naegleria fowleri, Nocardia asteroides, Nocardia species, Oestroidea, Caliphoridae, Sarcophagidae, Onchocerca volvulus, Opisthorchis viverrini, Opisthorchis felineus, Clonorchis Sinensis, Paracoccidioides brasiliensis, Paragonimus africanus, Paragonimus caliensis, Paragonimus kellicotti, Paragonimus skriabini, Paragonimus uterobilateralis, Paragonimus westermani, Paragonimus species, Paramyxoviridae, parasitic dipterous fly larvae, Parvovirus B 19, Pasteurella genus, Pediculus humanus, Pediculus humanus capitis, Pediculus humanus corporis, Phthirus pubis , Piedraiahortae, Plasmodium vivax, Plasmodium ovale curtisi, Plasmodium ovale wallikeri, Plasmodium malariae, Plasmodium knowlesi, Pneumocystis jirovecii , Polyomaviridae, Poxviridae, Prevotella genus, PRNP Pthirus pubis, Pulex irritans , Reoviridae, Rhabdoviridae, Rhinosporidium seeberi , coronaviruses, Rift Valley fever virus, Sabia, Salmonella enterica Subsp. enterica , serovar typhi, Salmonella genus, Sarcocystis bovihominis, Sarcocystis suihominis, Sarcoptes scabiei , SARS coronavirus, Schistosoma haematobium, Schistosoma japonicum, Schistosoma mansoni and Schistosoma intercalatum, Schistosoma mekongi, Shigella genus, Sin Nombre virus, Spirometra erinaceieuropaei, Sporothrix schenckii, Strongyloides stercoralis, Taenia genus, Taenia saginata, Taenia solium , the bacterial family Enterobacteriaceae, Thelazia californiensis, Thelazia callipaeda , Togaviridae, Toxocara canis, Toxocara cati, Trichinella spiralis, Trichinella britovi, Trichinella nelsoni, Trichinella nativa, Trichobilharzia regenti , Schistosomatidae, Trichophyton genus, Trichophyton tonsurans, Trichosporon beigelii, Trichuris trichiura, Trichuris trichiura, Trichuris vulpis, Trypanosoma brucei, Tunga penetrans , Urea plasma urealyticum, Variola major, Variola minor , Venezuelan equine encephalitis virus, Vibrio cholerae , West Nile virus, Wuchereria bancrofti, Wuchereria bancrofti, Yersinia enterocolitica, Yersinia pestis , and Yersinia pseudo tuberculosis.

16. The method of claim 1 , further comprising analyzing the microbial cell-free DNA and identifying infectious or pathogenic microbes in the mammalian host based on the microbial cell-free DNA.

17. The method of claim 1 , wherein the microbial cell-free nucleic acids are derived from at least one microbe selected from the group consisting of: Bordetella, Escherichia, Francisella, Pseudomonas, Salmonella, Shigella, Vibrio, Yersinia, Aspergillus, Pneumocystis, Stachybotrys , Anellovirus, and Bunyaviridae.

18. The method of claim 17 , wherein the microbial cell-free nucleic acids comprise cell-free DNA.

19. The method of claim 17 , wherein the at least one microbe is at least one bacterium selected from the group consisting of Bordetella, Escherichia, Francisella, Pseudomonas, Salmonella, Shigella, Vibrio , and Yersinia.

20. The method of claim 17 , wherein the at least one microbe is at least one fungus selected from the group consisting of: Aspergillus, Pneumocystis , and Stachybotrys.

21. The method of claim 17 , wherein the at least one microbe is at least one virus selected from the group consisting of: Anellovirus and Bunyaviridae.

22. The method of claim 1 , further comprising analyzing the microbial cell-free nucleic acids and identifying infectious or pathogenic microbes in the mammalian host based on the microbial cell-free nucleic acids.

23. The method of claim 20 , wherein the analyzing comprises performing next generation sequencing of the microbial cell-free nucleic acids, to generate microbial cell-free nucleic acid sequence reads.

24. The method of claim 1 , wherein the cell-free nucleic acids do not comprise an artificially fragmented nucleic acid.

25. The method of claim 1 , comprising enriching the plasma sample for microbial cell-free nucleic acids in the length interval range of from about 10 to about 60 base pairs.

26. The method of claim 1 , comprising enriching the plasma sample for microbial cell-free nucleic acids in the length interval range of from about 240 to about 280 base pairs.

27. The method of claim 1 , comprising enriching the plasma sample for microbial cell-free nucleic acids in the length interval range of from about 425 to about 475 base pairs.

28. The method of claim 1 , wherein the removing or physically isolating in (b) comprises performing electrophoresis.

29. The method of claim 1 , wherein the removing or physically isolating in (b) comprises binding the cell-free nucleic acids to a solid support.

30. The method of claim 1 , wherein the solid support comprises magnetic beads.

Assignments (2)
SECURITY INTEREST Recorded Apr 29, 2024
From: KARIUS, INC.
To: OXFORD FINANCE, LLC
Reel/Frame 067247/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: BLAUWKAMP, TIMOTHY A.; CHRISTIANS, FRED; VILFAN, IGOR D.; SMITH, SCOTT; KERTESZ, MICHAEL
To: KARIUS, INC.
Reel/Frame 065561/0077 →
Continuity (4)
Continuation 15157374 · May 17, 2016
Provisional Application 62334348 · May 10, 2016
Provisional Application 62163273 · May 18, 2015
Related Publication 20220154246A1 · May 19, 2022
References Cited (134)
US 6753137B2 · Lo et al. · 2004 [cited by applicant]
US 6759217B2 · Kopreski et al. · 2004 [cited by applicant]
US RE39920E · Umansky et al. · 2007 [cited by applicant]
US 7803929B2 · Melkonyan et al. · 2010 [cited by applicant]
US 7914982B2 · Melkonyan et al. · 2011 [cited by applicant]
US 7973154B2 · Melkonyan et al. · 2011 [cited by applicant]
US 8318434B2 · Cuppens · 2012 [cited by applicant]
US 8486626B2 · Umansky et al. · 2013 [cited by applicant]
US 8682592B2 · Rabinowitz et al. · 2014 [cited by applicant]
US 8703652B2 · Quake et al. · 2014 [cited by applicant]
US 9892230B2 · Lo et al. · 2018 [cited by applicant]
US 9976181B2 · Christians et al. · 2018 [cited by applicant]
US 10240200B2 · Koh et al. · 2019 [cited by applicant]
US 10450620B2 · De Vlaminick et al. · 2019 [cited by applicant]
US 10697008B2 · Blauwkamp et al. · 2020 [cited by applicant]
US 11111520B2 · Blauwkamp et al. · 2021 [cited by applicant]
US 20040209299A1 · Pinter et al. · 2004 [cited by applicant]
US 20050202414A1 · Jia et al. · 2005 [cited by applicant]
US 20060073506A1 · Christians et al. · 2006 [cited by applicant]
US 20060121452A1 · Dhallan · 2006 [cited by examiner]
US 20060183107A1 · Melkonyan · 2006 [cited by examiner]
US 20060292585A1 · Nautiyal et al. · 2006 [cited by applicant]
US 20100068711A1 · Umansky · 2010 [cited by examiner]
US 20100297710A1 · Hoyal-Wrightson et al. · 2010 [cited by applicant]
US 20110257031A1 · Bodeau et al. · 2011 [cited by applicant]
US 20110294699A1 · Lee et al. · 2011 [cited by applicant]
US 20120021412A1 · Melkonyan et al. · 2012 [cited by applicant]
US 20120077185A1 · Oliphant et al. · 2012 [cited by applicant]
US 20120100549A1 · Eshoo · 2012 [cited by examiner]
US 20120190663A1 · Gornik et al. · 2012 [cited by applicant]
US 20120295810A1 · Quake et al. · 2012 [cited by applicant]
US 20130024127A1 · Stuelpnagel et al. · 2013 [cited by applicant]
US 20130178544A1 · Melkonyan et al. · 2013 [cited by applicant]
US 20130224740A1 · Thierry et al. · 2013 [cited by applicant]
US 20130237431A1 · Lo et al. · 2013 [cited by applicant]
US 20130245961A1 · Lo et al. · 2013 [cited by applicant]
US 20130252835A1 · Koh et al. · 2013 [cited by applicant]
US 20130253844A1 · Lo et al. · 2013 [cited by applicant]
US 20130303461A1 · Iafrate et al. · 2013 [cited by applicant]
US 20130310260A1 · Kim et al. · 2013 [cited by applicant]
US 20140064669A1 · Kachmar · 2014 [cited by applicant]
US 20140066317A1 · Talasaz · 2014 [cited by applicant]
US 20140147851A1 · Qian et al. · 2014 [cited by applicant]
US 20140180594A1 · Kim et al. · 2014 [cited by applicant]
US 20140227691A1 · May et al. · 2014 [cited by applicant]
US 20140242582A1 · Oliphant et al. · 2014 [cited by applicant]
US 20140274740A1 · Srinivasan · 2014 [cited by examiner]
US 20140363812A1 · Micalef · 2014 [cited by applicant]
US 20160017420A1 · Koh et al. · 2016 [cited by applicant]
US 20160304953A1 · Chen et al. · 2016 [cited by applicant]
US 20170145507A1 · Koh et al. · 2017 [cited by applicant]
US 20170145508A1 · Koh et al. · 2017 [cited by applicant]
US 20170145509A1 · Koh et al. · 2017 [cited by applicant]
US 20190256891A1 · Blauwkamp et al. · 2019 [cited by applicant]
US 20200291457A1 · Blauwkamp et al. · 2020 [cited by applicant]
US 20220195496A1 · Ahmed et al. · 2022 [cited by applicant]
EP 1856295A2 · 2007 [cited by applicant]
EP 1885877A2 · 2008 [cited by applicant]
EP 2351857A1 · 2011 [cited by applicant]
EP 2612926A1 · 2013 [cited by applicant]
EP 2728014A1 · 2014 [cited by applicant]
JP 2008536481A · 2008 [cited by applicant]
JP 2010537650A · 2010 [cited by applicant]
WO WO9408239A1 · 1994 [cited by applicant]
WO WO2009102470A2 · 2009 [cited by applicant]
WO WO2011057061A1 · 2011 [cited by applicant]
WO WO2011143659A2 · 2011 [cited by applicant]
WO WO2012088348A2 · 2012 [cited by applicant]
WO WO2012135815A2 · 2012 [cited by applicant]
WO WO2012159023A2 · 2012 [cited by applicant]
WO WO2012168815A2 · 2012 [cited by applicant]
WO WO2013043922A1 · 2013 [cited by applicant]
WO WO2013052907A2 · 2013 [cited by applicant]
WO WO2013109981A1 · 2013 [cited by applicant]
WO WO2013113012A2 · 2013 [cited by applicant]
WO WO2013132305A1 · 2013 [cited by applicant]
WO WO2013134261A1 · 2013 [cited by applicant]
WO WO2013156627A1 · 2013 [cited by applicant]
WO WO2013159035A2 · 2013 [cited by applicant]
WO WO2013188846A1 · 2013 [cited by applicant]
WO WO2014019275A1 · 2014 [cited by applicant]
WO WO2014029792A1 · 2014 [cited by applicant]
WO WO2014039556A1 · 2014 [cited by applicant]
WO WO2014068075A1 · 2014 [cited by applicant]
WO WO2014128453A1 · 2014 [cited by applicant]
WO WO2014149134A2 · 2014 [cited by applicant]
WO WO2014151117A1 · 2014 [cited by applicant]
WO WO2014179805A1 · 2014 [cited by applicant]
WO WO2015048535A1 · 2015 [cited by applicant]
WO WO2015058079A1 · 2015 [cited by applicant]
WO WO2015070086A1 · 2015 [cited by examiner]
WO WO2015085105A1 · 2015 [cited by applicant]
WO WO2016187234A1 · 2016 [cited by applicant]
WO WO2018045359A1 · 2018 [cited by applicant]
WO WO2020106893A1 · 2020 [cited by applicant]
WO WO2020106987A1 · 2020 [cited by applicant]
WO WO2022140302A1 · 2022 [cited by applicant]
WO WO2022150725A1 · 2022 [cited by applicant]
WO WO2022174117A1 · 2022 [cited by applicant]
Anisimova, et al. Thermolabile duplex-specific nuclease. Biotechnology Letters, Feb. 2009, vol. 31, Issue 2, pp. 251-257. [cited by applicant]
Arbabi, et al., Cell-free DNA fragment-size distribution analysis for non-invasive prenatal CNV prediction. Bioinformatics, vol. 32, Issue 11, Jun. 1, 2016, pp. 1662-1669. [cited by applicant]
Arroyo, J.D. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma, 2011. Proc. Natl. Acad. Sci. USA vol. 108, pp. 5003-5008. [cited by applicant]
Barcelos Barra, et al., EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. Clinical Biochemistry, 2015; 48:976-981. [cited by applicant]
Begley, et al., The interaction between bacteria and bile. FEMS Microbiology review. 2005; 29: 625-651. [cited by applicant]
Burnham, et al. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. Sci Rep. Jun. 14, 2016;6:27859. doi: 10.1038/srep27859. [cited by applicant]
Burnham, et al. Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. Nat Commun. Jun. 20, 2018;9(1):2412. doi: 10.1038/s41467-018-04745-0. [cited by applicant]
Calvo, et al. A novel secreted endonuclease from Culex quinquefasciatus salivary glands. J Exp Biol. Jul. 2006;209(Pt 14):2651-9. [cited by applicant]
Chereji, et al. Quantitative MNase-seq accurately maps nucleosome occupancy levels. Genome Biol. Sep. 13, 2019;20(1):198. doi: 10.1186/s13059-019-1815-z. [cited by applicant]
De Vlaminck, et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell. Nov. 21, 2013;155(5):1178-87. doi: 10.1016/j.cell.2013.10.034. [cited by applicant]
European search report and opinion dated Sep. 20, 2018 for EP Application No. 16797172.0. [cited by applicant]
Fleischhacker, et al. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. Nov. 20, 2011;412(23-24):2085-8. doi: 10.1016/j.cca.2011.07.011. Epub Jul. 23, 2011. [cited by applicant]
Han, et al. The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. Am J Hum Genet. Feb. 6, 2020;106(2):202-214. doi: 10.1016/j.ajhg.2020.01.008. Epub Jan. 30, 2020. [cited by applicant]
Harkins, et al. A novel NGS library preparation method to characterize native termini of fragmented DNA. Nucleic Acids Res. May 7, 2020;48(8):e47. doi: 10.1093/nar/gkaa128. [cited by applicant]
Highlander, Sarah K. High throughput sequencing methods for microbiome profiling: application to food animal systems. Anim Health Res Rev. Jun. 2012;13(1):40-53. doi: 10.1017/S1466252312000126. [cited by applicant]
International search report with written opinion dated Oct. 14, 2016 for PCT/US2016/032936. [cited by applicant]
Matvienko, et al. Consequences of Normalizing Transcriptomic and Genomic Libraries of Plant Genomes Using a Duplex-Specific Nuclease and Tetramethylammonium Chloride. PloS one 8.2 (2013): e55913. [cited by applicant]
Mojsin, et al. Rapid detection and purification of sequence specific DNA binding proteins using magnetic separation. J. Serb. Chem. Soc. 71 (2) 135-141 (2006) DOI: 10.2298/JSC0602135M. [cited by applicant]
Nilsen, et al. The enzyme and the cDNA sequence of a thermolabile and double-strand specific DNase from Northern shrimps ( [cited by applicant]
Phylochip: Berkeley Lab Earth Sciences Division website. Accessed Apr. 2015. http://esd.lbl.gov/research/facilities/andersenlab/phylochip.html. [cited by applicant]
Saukkonen, et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin Chem. Jun. 2008;54(6):1000-7. doi: 10.1373/clinchem.2007.101030. Epub Apr. 17, 2008. [cited by applicant]
Shagin, et al. A novel method for SNP detection using a new duplex-specific nuclease from crab hepatopancreas. Genome Res. Dec. 2002;12(12):1935-42. [cited by applicant]
Song, et al. Nuclease-assisted suppression of human DNA background in sepsis. PLoS One. Jul. 30, 2014;9(7):e103610. doi: 10.1371/journal.pone.0103610. eCollection 2014. [cited by applicant]
Yamada, et al. PrimerStation: a highly specific multiplex genomic PCR primer design server for the human genome. Nucleic Acids Res. Jul. 1, 2006;34(Web Server issue):W665-9. [cited by applicant]
Blauwkamp, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. Apr. 2019;4(4):663-674. doi: 10.1038/s41564-018-0349-6. Epub Feb. 11, 2019. [cited by applicant]
Deligezer, et al., Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma. Clinical Chemistry, 2008; 54(7): 1125-1131. [cited by applicant]
Nishida, et al., Genome-wide maps of mononucleosomes and dinucleosomes containing hyperacetylated histones of Aspergillus fumigatus. PlosOne, Mar. 2010; 5(3): e9916. [cited by applicant]
Notice of Allowance dated Jul. 26, 2021 for U.S. Appl. No. 15/157,374. [cited by applicant]
Office action dated Feb. 7, 2020 for U.S. Appl. No. 15/157,374. [cited by applicant]
Office action dated May 8, 2019 for U.S. Appl. No. 15/157,374. [cited by applicant]
Office action dated Aug. 18, 2020 for U.S. Appl. No. 15/157,374. [cited by applicant]
Office action dated Sep. 28, 2018 for U.S. Appl. No. 15/157,374. [cited by applicant]
Zhou, et al. A novel method of selective removal of human DNA improves PCR sensitivity for detection of [cited by applicant]
Han et al., Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing. Theranostics 10(12): 5501-5513 (2020). [cited by applicant]
Extended European Search Report for European Patent Application No. EP24194575.7 dated Dec. 3, 2024. [cited by applicant]